Role of Reactivating Mutant p53 Protein in Suppressing Growth and Metastasis of Triple-Negative Breast Cancer

References

• Siegel RL, Miller KD, Jemal A. A cancer statistics. CA Cancer J Clin. 2020;70:7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Aysola K, Desai A, Welch C, et al. Triple negative breast cancer – an overview. Hered Genet. 2013;2013(Suppl 2):001. doi:10.4172/2161-1041.S2-001
   PubMedGoogle Scholar
• Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015;12:106–116. doi:10.7497/j.issn.2095-3941.2015.0030
   PubMed Web of Science ®Google Scholar
• Park SY, Choi JH, Nam JS. Targeting cancer stem cells in triple-negative breast cancer. Cancers. 2019;11:965. doi:10.3390/cancers11070965
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70. doi:10.1038/nature11412
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Synnot NC, O’Grady S, Crown J. Targeting p53 for the treatment of cancer. Semin Cancer Biol. 2020;S1044–579X(20):30160–30167.
   Google Scholar
• Kaur RP, Vasudeva K, Kumar R, Munshi A. Role of p53 gene in breast cancer: focus on mutation spectrum and therapeutic strategies. Curr Pharm Des. 2018;24:3566–3575. doi:10.2174/1381612824666180926095709
   PubMed Web of Science ®Google Scholar
• Lane DP. Cancer. P53, guardian of the genome. Nature. 1992;358:15–16. doi:10.1038/358015a0
   PubMed Web of Science ®Google Scholar
• Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88(3):323–331. doi:10.1016/S0092-8674(00)81871-1
   PubMed Web of Science ®Google Scholar
• Zilfou JT, Lowe SW. Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol. 2009;1(5):00a001883. doi:10.1101/cshperspect.a001883
   PubMed Web of Science ®Google Scholar
• Perdrix A, Najem A, Saussez S, et al. PRIMA-1 and PRIMA-1Met (APR-246): from mutant/wild type p53 reactivation to unexpected mechanisms underlying their potent anti-tumor effect in combinatorial therapies. Cancers. 2017;9:172–188. doi:10.3390/cancers9120172
   PubMed Web of Science ®Google Scholar
• Menichini P, Monti P, Speciale A, et al. Antitumor effects of PRIMA-1 and PRIMA-1Met (APR246) in hematological malignancies: still a mutant p53-dependent affair? Cells. 2021;10(1):98–112. doi:10.3390/cells10010098
   PubMed Web of Science ®Google Scholar
• Klymkowsky MW, Savagner P. Epithelial-mesenchymal transition. Am J Pathol. 2009;174(5):1588–1593. doi:10.2353/ajpath.2009.080545
   PubMed Web of Science ®Google Scholar
• Omar SI, Tuszynski J. The molecular mechanism of action of methylene quinuclidinone and its effects on the structure of p53 mutants. Oncotarget. 2018;9:37137–37156. doi:10.18632/oncotarget.26440
   PubMedGoogle Scholar
• Chen J. The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harb Perspect Med. 2016;6:a026104. doi:10.1101/cshperspect.a026104
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Synnott NC, Crown J. Mutant p53 in breast cancer: potential as a therapeutic target and biomarker. Breast Cancer Res Treat. 2018;170:213–219. doi:10.1007/s10549-018-4753-7
   PubMed Web of Science ®Google Scholar
• Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387:299–303. doi:10.1038/387299a0
   PubMed Web of Science ®Google Scholar
• Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol. 2003;13:49–58. doi:10.1016/S1044-579X(02)00099-8
   PubMed Web of Science ®Google Scholar
• Wassman CD, Baronio R, Demir O, et al. Computational identification of a transiently open L2/S3 pocket for reactivation of mutant p53. Nat Commun. 2013;4:1407. doi:10.1038/ncomms2361
   PubMed Web of Science ®Google Scholar
• Bykov VJN, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002;8:282–288. doi:10.1038/nm0302-282
   PubMed Web of Science ®Google Scholar
• Liang Y, Besch-Williford C, Cook MT, et al. APR-246 alone and in combination with a phosphatidylserine-targeting antibody inhibits lung metastasis of human triple-negative breast cancer cells in nude mice. Breast Cancer. 2019;11:249–259. doi:10.2147/BCTT.S208706
   PubMed Web of Science ®Google Scholar
• Lehmann S, Bykov VJN, Ali D, et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol. 2012;30:3633–3639. doi:10.1200/JCO.2011.40.7783
   PubMed Web of Science ®Google Scholar
• Liang Y, Mafuvadze B, Besch-Williford C, Hyder SM. A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts. Breast Cancer. 2018;10:53–67. doi:10.2147/BCTT.S156285
   PubMed Web of Science ®Google Scholar
• Liang Y, Besch-Williford C, Mafuvadze B, Brekken RA, Hyder S. Combined treatment with p53-activating drug APR-246 and a phosphatidylserine-targeting antibody, 2aG4, inhibits growth of human triple-negative breast cancer xenografts. Cancer Rep Rev. 2020;4:1–10. doi:10.15761/CRR.1000205
   Google Scholar
• Salim KY, Maleki Vareki S, Danter WR, Koropatnick J. COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo. Oncotarget. 2016;7(27):41363–41379. doi:10.18632/oncotarget.9133
   PubMedGoogle Scholar
• Synnott NC, O’Connell D, Crown J, Duffy MJ. COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells. Breast Cancer Res Treat. 2020;179(1):47–56. doi:10.1007/s10549-019-05435-1
   PubMed Web of Science ®Google Scholar
• Green JA, Von Euler M, Abrahmsen LB. Restoration of conformation of mutant p53. Ann Oncol. 2018;29:1325–1328. doi:10.1093/annonc/mdy057
   PubMed Web of Science ®Google Scholar
• Issaeva N, Bozko P, Enge M, et al. Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors. Nat Med. 2004;10:1321–1328. doi:10.1038/nm1146
   PubMed Web of Science ®Google Scholar
• Doggrell SA. RITA - a small-molecule anticancer drug that targets p53. Expert Opin Investig Drugs. 2005;14:739–742. doi:10.1517/13543784.14.6.739
   PubMed Web of Science ®Google Scholar
• Weilbacher A, Gutekunst M, Oren M, Aulitzky WE, van der Kuip H. RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38. Cell Death Dis. 2014;5:e1318. doi:10.1038/cddis.2014.284
   PubMed Web of Science ®Google Scholar
• Rivera MI, Stinson SF, Vistica DT, Jorden JL, Kenney S, Sausville EA. Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines. Biochem Pharmacol. 1999;57:1283–1295. doi:10.1016/S0006-2952(99)00046-5
   PubMed Web of Science ®Google Scholar
• Peyser BD, Hermone A, Salamoun JM, et al. Specific RITA modification produces hyperselective cytotoxicity while maintaining in vivo antitumor efficacy. Mol Cancer Ther. 2019;18:1765–1774. doi:10.1158/1535-7163.MCT-19-0185
   PubMed Web of Science ®Google Scholar
• Kravchenko JE, Ilyinskaya GV, Komarov PG, et al. Small-molecule RETRA suppresses mutant p53 bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci USA. 2008;105:6302–6307. doi:10.1073/pnas.0802091105
   PubMed Web of Science ®Google Scholar
• Zawacka-Pankau J, Selivanova G. Pharmacological reactivation of p53 as a strategy to treat cancer. J Intern Med. 2015;277:248–259. doi:10.1111/joim.12336
   PubMed Web of Science ®Google Scholar
• Sallman DA, DeZern AE, Guillermo Garcia-Manero DP, et al. Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J Clin Oncol. 2021;39:1584–1594. doi:10.1200/JCO.20.02341
   PubMed Web of Science ®Google Scholar
• Benakanakere I, Besch-Williford C, Ellersieck MR, Hyder SM. Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study. Endocr Relat Cancer. 2009;16(1):85–98. doi:10.1677/ERC-08-0069
   PubMed Web of Science ®Google Scholar